UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):September 7, 2017
Dextera Surgical, Inc.
(Exact Name of Registrant as Specified in its Charter)
| | |
Delaware (State or Other Jurisdiction of Incorporation) | 000-51772 (Commission File Number) | 94-3287832 (IRS Employer Identification No.) |
| |
900 Saginaw Drive, Redwood City, CA (Address of Principal Executive Offices) | 94063 (Zip Code) |
Registrant’s telephone number, including area code: (650) 364-9975
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item7.01.Regulation FD Disclosure.
The outstanding capital stock of Dextera Surgical Inc. as of the close of business on September 7, 2017, was as follows:
Shares of Common Stock: | 47,782,144 |
Shares of Series B Convertible Preferred Stock: | 273 |
From May 16, 2017, through September 7, 2017, Dextera Surgical has issued 8,243,137 shares of its Common Stock upon exercise of warrants sold in Dextera Surgical’s May 2017 public offering for total proceeds from these warrant exercises of $2,225,646.99.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | Dextera Surgical, Inc. | |
| | | | |
| | | |
Date:September 8, 2017 | | /s/ Robert Y. Newell | |
| | Robert Y. Newell | |
| | Chief Financial Officer | |
